Hemodynamic Change of Coronary Atherosclerotic Plaque After Evolocumab Treatment

NCT04416425 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2021-04-21

No results posted yet for this study

Summary

Compelling evidences indicate that lipid-lowering therapy can reduce the high-risk plaque feathers and improve the coronary flow reserve. This study is going to investigate the change of lesion-specific hemodynamic significance as determined by ML(Machine Learning)-based CT-FFR (Computed Tomography-Fractional Flow Reserve)after Evolocumab treatment.

Conditions

Sponsors & Collaborators

  • Zibo Central Hospital

    lead OTHER_GOV

Principal Investigators

  • Bo Li, Doctor · Zibo Central Hospital

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-30
Primary Completion
2022-12-31
Completion
2023-02-27

Countries

  • China

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04416425 on ClinicalTrials.gov